ARAY Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -1.15% compared to Accuray's net margin of --. Accuray's return on equity of 1.47% beat Perspective Therapeutics's return on equity of --.

Accuray has a consensus price target of $5.63, signalling upside risk potential of 277.52%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 494.75%. Given that Perspective Therapeutics has higher upside potential than Accuray, analysts believe Perspective Therapeutics is more attractive than Accuray.

Accuray has a beta of 1.304, which suggesting that the stock is 30.444% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $113.2M, which are larger than Perspective Therapeutics quarterly revenues of --. Accuray's net income of -$1.3M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Accuray's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.33x versus 15.67x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -1.15% compared to Accuray's net margin of 28.26%. Accuray's return on equity of 1.47% beat ResMed's return on equity of 25.76%.

Accuray has a consensus price target of $5.63, signalling upside risk potential of 277.52%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 8.8%. Given that Accuray has higher upside potential than ResMed, analysts believe Accuray is more attractive than ResMed.

Accuray has a beta of 1.304, which suggesting that the stock is 30.444% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Accuray pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Accuray quarterly revenues are $113.2M, which are smaller than ResMed quarterly revenues of $1.3B. Accuray's net income of -$1.3M is lower than ResMed's net income of $365M. Notably, Accuray's price-to-earnings ratio is -- while ResMed's PE ratio is 27.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.33x versus 7.14x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -1.15% compared to Accuray's net margin of -1226.82%. Accuray's return on equity of 1.47% beat VolitionRX's return on equity of --.

Accuray has a consensus price target of $5.63, signalling upside risk potential of 277.52%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 465.02%. Given that VolitionRX has higher upside potential than Accuray, analysts believe VolitionRX is more attractive than Accuray.

Accuray has a beta of 1.304, which suggesting that the stock is 30.444% more volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $113.2M, which are larger than VolitionRX quarterly revenues of $474.5K. Accuray's net income of -$1.3M is higher than VolitionRX's net income of -$5.8M. Notably, Accuray's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.33x versus 36.30x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -1.15% compared to Accuray's net margin of -10.04%. Accuray's return on equity of 1.47% beat Xtant Medical Holdings's return on equity of -35.34%.

Accuray has a consensus price target of $5.63, signalling upside risk potential of 277.52%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 225.89%. Given that Accuray has higher upside potential than Xtant Medical Holdings, analysts believe Accuray is more attractive than Xtant Medical Holdings.

Accuray has a beta of 1.304, which suggesting that the stock is 30.444% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $113.2M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Accuray's net income of -$1.3M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Accuray's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.33x versus 0.61x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.